Cardiometabolic & kidneyCohort study
Metabolic syndrome is associated with similar long-term prognosis in those living with and without obesity: an analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004–2015 studies
- Prospective cohort study
- nationwide
- primary care
Authors' conclusion
MetS is associated with increased all-cause mortality risk in non-obese and obese patients. In patients without MetS, obesity remains significantly associated with mortality.
Study context
- Population
- Primary care patients in Poland, LIPIDOGRAM studies 2004, 2006 and 201544,620 with follow-up
- Participants
- 45,615 patients
- Exposure
- Metabolic syndrome (MetS) vs no MetS, by obesity status
- Outcome
- Long-term all-cause mortality
- Follow-up
- Median 15.3 years
Main finding
As reported in the abstract
All-cause mortality
Hazard ratio (95% CI)
Obese with MetS vs Obese without MetSNCEP/ATP III criteria
1.88(1.79–1.99)
Obese with MetS vs Obese without MetSJIS criteria
1.93(1.82–2.04)
Non-obese with MetS vs Non-obese without MetSNCEP/ATP III criteria
2.11(1.85–2.40)
Non-obese with MetS vs Non-obese without MetSJIS criteria
1.7(1.56–1.85)
Obese without MetS vs Non-obese without MetSNCEP/ATP III criteria
1.16(1.10–1.23)
Obese without MetS vs Non-obese without MetSJIS criteria
1.22(1.15–1.30)
Observational data: associations, not effects.
Further findings
MetS prevalence
- MetS by NCEP/ATP III criteria
- 14 202 (31%)
- MetS by Joint Interim Statement (JIS) criteria
- 17 216 (37.7%)
Original publication
Metabolic syndrome is associated with similar long-term prognosis in those living with and without obesity: an analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004–2015 studies. Eur J Prev Cardiol. Published 11 April 2023. doi:10.1093/eurjpc/zwad101
Summarised from the published abstract; every number is checked against it